1.Clinical Observation of Shenqiluotong Capsule on 100 Patients with Diabetes Mellitus Crura Angiopathy
Hongwei ZHAI ; Yucheng XU ; Dujin WANG
Chinese Journal of Information on Traditional Chinese Medicine 2006;0(06):-
Objective To observe the clinical effect of Shenqiluotong capsule on diabetes mellitus crura angiopathy.Methods Two hundred patients with diabetes mellitus crura angiopathy were randomly divided into two groups.One hundred patients in the treatment group were administrated Shenqiluotong capsule and enteric-coated aspirin tablet orally.One hundred patients in the control group were only given enteric-coated aspirin tablet orally.The effectiveness,clinical symptom and sign,glucose,blood fat,hemodynamics,crura artery diameter,peak value rate,blood flow volume and side effect were observed before and after treatment.Results The total effective rate in the treatment group and the control group were 89 % and 71% respectively(P
2.Targeting effect of TLS9a nucleic acid aptamer on mice hepatic cancer cells
Liping WEI ; Dujin WANG ; Tiantian ZOU ; Anxing FEI
Chongqing Medicine 2017;46(26):3623-3625,3628
Objective To investigate the targeting effect of TLS9a nucleic acid aptamer on mice hepatic cancer cells.Methods The liposome modified with maleimide and loading doxorubicin(DOX) was prepared,then TLS9a nucleic acid aptamer modified by FITC fluorescence and sulfydryl was synthesized,which was coupled to the liposome surface.The entrapment efficiency of DOX was detected by UV spectrophotometry.The dynamic light scattering(DLS) was applied to measure the particle size of nanoparticles and the potential distribution.The uptake of DOX in mice hepatic cancer cells was detected by the Nikon inverted microscope and the mean fluorescence intensity of liposome/DOX and TLS9a-liposome/DOX was detected by flow cytometry.The cells activity was detected by MTT.Results Flow cytometry assay showed that the binding rate of TLS9a nucleic acid aptamer with BNL.1ME.A.7R.1 mice hepatic cancer cells was 54.1%.TLS9a-liposome particle size distribution was in (116.0 ± 5.0)nm.TLS9a-liposome/DOX released DOX quickly at pH 5.0,and the release amount in 72 h was more than 70 % of the total release amount.TLS9a-liposome/DOX effectively inhibited the growth of mice hepatic cancer cells BNL.1ME.A.7R.1.Conclusion TLS9a nucleic acid aptamer could specifically combined with mice hepatic cancer cells BNL.1ME.A.7R.1,which could be used to detect mice hepatic cancer cells.